key: cord-0689965-hds7uj8u
authors: Mattocks, C. J.; Ward, D.; Mackay, D. J.
title: RT-RC-PCR: a novel and highly scalable next-generation sequencing method for simultaneous detection of SARS-COV-2 and typing variants of concern
date: 2021-03-05
journal: nan
DOI: 10.1101/2021.03.02.21252704
sha: cb295f3cc198a4d718f6977cf16f5f5234c60001
doc_id: 689965
cord_uid: hds7uj8u

We describe a novel assay method: reverse-transcription reverse-complement polymerase chain reaction (RT-RC-PCR), which rationalises reverse transcription and NGS library preparation into a single closed tube reaction. By simplifying the analytical process and cross-contamination risks, RT-RC-PCR presents disruptive scalability and economy while using NGS and LIMS infrastructure widely available across health service, institutional and commercial laboratories. We present a validation of RT-RC-PCR for the qualitative detection of SARS-CoV-2 RNA by NGS. The limit of detection is comparable to real-time RT-PCR, and no obvious difference in sensitivity was detected between extracted nasopharyngeal swab (NPS) RNA and native saliva samples. The end point measurement of RT-RC-PCR is NGS of amplified sequences within the SARS-CoV-2 genome; we demonstrated its capacity to detect different variants using amplicons containing delH69-V70 and N501Y, both of which emerged in the UK Variant of Concern B.1.1.7 in 2020. In summary, RT-RC-PCR has potential to facilitate accurate mass testing at disruptive scale and cost, with concurrent detection of variants of concern.

The Coronavirus Disease 2019 (COVID-19) pandemic has caused detrimental social and economic effects worldwide and, at the time of writing, is responsible for over 2.5 million deaths globally.

The etiopathogenic agent responsible for COVID-19 is the novel SARS-CoV-2 coronavirus. The gold standard test for molecular diagnosis of current SARS-CoV2 infection requires RNA extraction from the given sample followed by real-time qualitative detection of viral RNA by real-time reverse-transcription PCR (rRT-PCR).

Whilst different sample types are known to yield different positivity rates through the course of an infection [1] , practicalities of sample collection and subsequent processing are the predominant consideration. Generally, RNA has been extracted from nasophyaryngeal swab (NPS) samples collected by healthcare personnel, but more recently saliva has become a popular sample type due to the ease of self collection, though it remains uncertain which sample type is more valid for testing.

Attempts have been made to rationalise the test procedure by simplifying the RNA extraction step or eliminating it entirely [2] [3] [4] [5] [6] . Such refinements facilitate more streamlined laboratory processing, reduce cost and ease the issue of supply of critical reagents.

Reverse transcription loop mediated isothermal amplification (RT-LAMP) has been developed as an alternative to rRT-PCR [7 8] . Because this reaction uses strand displacement instead of thermal cycling, amplification is extremely fast, and can significantly reduce the time required for the measurement phase of the test. It is worth noting that both rRT-PCR and RT-LAMP rely on indirect fluorometric measurement and as such may require secondary confirmation that the signal has derived from the desired target typically by melt analysis of the amplicon.

Expansion of viral testing to community-based or population-based screening is necessary to detect asymptomatic transmission and potentially restore freedom to interpersonal interactions within and between communities.

A laboratory setup suitable for such testing must be capable of handling in the order of tens of thousands of tests per day and the test itself must be sensitive and specific, economical, rapid and robust; and preferably use widely-available and existing infrastructure. Key challenges to scaling include the timely and safe delivery of samples to the testing site, the extraction of RNA, the robust supply of reagents . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint 4 that are in high demand, and the simplification of laboratory testing processes so that they can be effectively automated. To achieve the required scale of testing, a high level of parallelisation is required in the measurement phase of the test.

Typically rRT-PCR and RT-LAMP tests can be analysed in batches of up to 96 samples. Even considering fast turnaround on the analysis platforms, multiple instruments are required to analyse tens of thousands of tests per day.

Next generation sequencing (NGS) represents an alternative platform with the capacity to analyse many tens of thousands of samples in a single instrument run.

Individual samples can be labelled with short unique identifying DNA sequences (indexes) prior to sequencing so that the data can be assigned to samples during analysis. The challenge with this approach is streamlining the library preparation process and providing sufficient indexes for the analysis scale required without risk of cross-contamination between samples.

Conventional amplicon-based library preparation methods require separate reactions to amplify the targets and subsequently apply the sample indexes. This process is complex in terms of automation and presents an inherent risk of cross contamination due to the opening and manipulation of tubes containing exponentially amplified target material prior to the application of indexes.

Here we describe a novel assay method: reverse-transcription reverse-complement polymerase chain reaction (RT-RC-PCR). RC-PCR rationalises NGS library preparation into a single closed tube reaction, thus simplifying the analytical process and eliminating risks of cross-contamination. By integrating reverse transcription (RT) into RC-PCR we have developed a single-tube SARS-CoV-2 RNA detection assay using NGS. RT-RC-PCR presents disruptive scalability and economy while using NGS and LIMS infrastructure widely available across health service, institutional and commercial laboratories.

We present a validation of RT-RC-PCR for the qualitative detection of SARS-CoV-2 RNA by NGS in both extracted nasopharyngeal swab (NPS) RNA and native saliva samples.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Kit v2 (Anatolia Geneworks ABCOW5), assaying E and ORF1AB, using the Qiagen . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint Rotorgene as the analysis platform. Extracted NPS samples in which SARS-CoV-2 was detected using SoC testing are here designated 'positive controls', and those in which SARS-CoV-2 was not detected are designated 'negative controls'.

Saliva samples from healthy (nonsymptomatic) anonymised controls were given in the morning before eating or drinking. Aliquots of saliva (100μl) were placed in screw-capped tubes, and heat-treated to 95 ᵒ C for 5 minutes before storage at -20 ᵒ C.

For the direct saliva test 5μl aliquots were assayed in exactly the same way as extracted RNA. Cultured, UV-inactivated SARS-CoV-2 was a generous gift from Dr Karl Staples, University of Southampton.

Each RT-RC-PCR reaction requires five oligonucleotides; two RC-probes (specific to the amplicon) two universal primers (specific to the sample) and a reverse transcription primer. Figure 1 shows the logical principle of RT-RC-PCR.

The core technology is Reverse complement PCR (RC-PCR), which is a simple, robust method for uniquely indexing samples for downstream analysis in individual, closed tube reactions. The reaction is analogous to a standard PCR except that target specific primers are not provided in the reaction mix. Instead of each primer, a system comprising two oligonucleotides, a universal indexing primer (UIP) and a reverse complement probe (RC-probe) (Figure 1a ), is used to generate fully formed primers as the reaction proceeds ( Figure 1b ). The UIP includes the necessary sequencing adaptor at the 5' end, a sample identification sequence (10bp index sequence) in the middle and a universal sequence at the 3' end. Note that the universal primer has no target binding sequence. The RC-probe comprises the reverse complement of the desired target binding sequence for the primer at the 5'end, and the 3' end is able to hybridise to the universal sequence of the UIP ( Figure 1b ). Thus bound, the UIP can be extended, using the RC-probe as the template, to yield fully formed, indexed primers (Figure 1c ), which are then available to amplify the template in subsequent rounds of the PCR. A single set of target specific probes can be used to simultaneously amplify and index many thousands of samples using an appropriate number of uniquely indexed UIPs (Figure 1d ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint 7

Combining this system with an initial reverse transcription allows direct amplification from RNA targets and sample specific indexing in a one-step, single tube reaction.

For high capacity testing, the only subsequent processing required is product pooling, clean-up and Illumina sequencing (Figure 1e ).

RT-RC-PCR assay.

Each RT-RC-PCR, in a final volume of 20µl, included: 1x RT-PCR mix containing reverse transcriptase and PCR polymerase; 50pM of each forward and reverse RCprobe specific to the E and RPP30 amplicons, 1nM IPs, and 5µl sample. The reaction comprised a reverse transcription step followed by 40 cycles of PCR.

Amplification products were pooled and quantified by Qubit before clean-up, dilution and sequencing.

Whilst our assay is agnostic to sequencing platform, the critical parameter for any next generation sequencing approach is the number of reads that can be generated per given time frame. In this context Illumina sequencing provides the highest available 'per-run' capacity for any current platform. Our NGS analysis was performed using Illumina V2 Micro flowcells, using a dual indexing regime. Typically we analysed 200-400 samples per run; this read format and scale of analysis was purposely excessive in order to allow modelling to determine minimum read depth requirements and read length for a robust clinical test.

The calling algorithm was developed using a training set comprising 12 independent series of Twist synthetic RNA control diluted in RNA samples that had previously tested negative by the SoC test (2000 to 0 genome copies /μl). Any sample with an aggregate of less than 100 reads assigned to the E amplicon and RPP30 amplicons combined was deemed to have failed and excluded from further analysis. All remaining analyses in the training set were subjected to simple logistic regression using the proportion of mapped reads that aligned to the E amplicon as the sole parameter (i.e. E reads / E reads + RPP30 reads, see Figure 2 (d)). Logistic regression was performed using the real-statistics Excel add-in from . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The limit of detection (LoD) was assessed using quantified synthetic SARS-CoV-2 RNA (Twist). This RNA was spiked into pooled negative control NPS samples and used to generate dilution series from 2000 to 0 genome copies/μl. Figure 2 summarises the results of these analyses in terms of the raw read counts assigned to the E amplicon and the RPP30 control amplicon. As expected, the E amplicon Table 2 presents the results of blinded analysis performed using RT-RC-PCR and the calling algorithm derived above. Of the 192 samples analysed, 78/78 positives called by rRT-PCR were correctly identified, two negatives were failed because the total mapped read count was less than 100 (1% overall failure rate), and 109/112 of the remaining negatives were correctly identified. Raw calculated sensitivity was 95.4-100% (95% CI) and specificity was 92.4-99.4% (95% CI). These analyses were carried out on a single Illumina V2 Micro flowcell, which represents an allocation of approximately 20,000 reads per sample. Since available reads will . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint ultimately determine the feasible sample capacity per run, we performed random sub-sampling of these data to model performance characteristics with fewer reads available per sample. At 10 fold sub-sampling, which represents the performance with 2,000 samples on a V2 Micro flowcell run, with an average of 2,000 reads available per sample, the calculated performance metrics were virtually unchanged: Sensitivity was 95.3-100% (95% CI) and specificity was 93.5-99.8% (95% CI) with an overall failure rate of 3% (6/192).

Validation for use with saliva samples. In a final test, UV-inactivated SARS-CoV-2 was spiked into native saliva, heattreated at 95°C for 5 minutes and then left at ambient temperature for 2.5 hours before preparation of dilution series and assay by RT-RC-PCR. Compared with a parallel dilution series assayed without delay, there was no apparent reduction in detection of viral amplicon (Figure 4b) . Overall, these data convincingly show the robustness of RT-RC-PCR to assaying native saliva.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint

Since our assay uses sequencing of particular parts of the SARS-CoV-2 genome as the end point measurement, we wanted to see if the assay was capable of detecting mutations and could thus have utility in typing and identifying variants of concern (VoC). Four sets of primers and RC-probes were designed to amplify regions surrounding N501Y (several VoC), delH69-V70 (UK VoC), K417N /K417T (several VoC) and E484K (several VoC). [11] [12] [13] [14] 17 of 32 RNA samples testing positive by the local SoC rRT-PCR were shown to harbour both the N501Y and delH69-V70 mutations present in the B.1.1.7 lineage which has emerged as a UK VoC (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach ment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf).

We have developed a novel method based on RT-RC-PCR, for the qualitative detection of SARS-CoV-2 in both extracted RNA and native saliva samples.

Validation studies, in comparison to rRT-PCR standard of care testing, show this method to perform robustly with high sensitivity and specificity and a low limit of detection. We have emulated a full analysis workflow using native saliva, including incubation at ambient temperature for up to 48 hours and a heat treatment viral inactivation step, with no apparent effect on performance. This testing format removes the requirement for an RNA extraction step, which is desirable in terms of cost, turn around time and availability of reagents. Interestingly, it appears the viral inactivation step performed with raw saliva essentially eliminates detection of the naked RNA control (Twist), but maintains detection of viral particles (UV inactivated control material). This suggests the test, in this form, is specific for viral particles and would not therefore detect post-infection RNA shedding, which has been noted as a potential issue in previous studies [15] [16] [17] [18] .

RT-RC-PCR has a number of major advantages in comparison to standard testing methodologies, making it suitable for laboratory based mass testing strategies.

The single closed tube reaction reverse transcribes RNA, amplifies cDNA target material and applies unique sample identification sequences. This approach . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint simplifies the testing process and minimises as far as possible the potential for cross-contamination. Importantly the assay also includes a multiplexed endogenous control, providing confidence in each individual assay as opposed to batch control.

Automation: Simplicity is absolutely critical for effective high capacity automation.

Our laboratory workflow is the simplest available for massively parallel analysis (PCR; Pool reaction products; Purify; Sequence). The core technology of RC-PCR is clinically validated and has been used in routine diagnostics at scale in the Wessex Genetics Service diagnostic laboratory for over 6 years. Capacity for further development: Using a duel index system sequencing can be performed on a MiSeq instrument in 5 hours. We have performed simulations using trimmed reads and single indexing, which indicate sequencing time could be reduced to around 3 hours. We have also demonstrated that the assay can be multiplexed and can be further adapted to include other desirable targets without increasing the complexity of the lab process, or significantly affecting per-sample cost of testing.

For example in the current context, amplicons could be added to allow differential diagnostics (Flu A & B, RSV) . We propose that RT-RC-PCR offers future capacity for detection of other infectious diseases. In conclusion, we have developed a novel SARS-CoV-2 test and demonstrated that its performance is broadly equivalent to rRT-PCR. The test performs robustly on native saliva samples and the workflow is extremely simple making it highly amenable to automation. Moreover, it is cheap, highly scalable and multiplexable, which offers the opportunity for more sophisticated tests. In a time when infection rates are falling and selection pressure is being exerted on the virus through application of vaccines, early detection of variants of concern will become increasingly important. We believe RT-RC-PCR has potential to facilitate accurate mass testing with concurrent detection of variants of concern.

Intellectual property

The core chemistry of RC-PCR is IP-protected, with the patent being owned by Salisbury NHS Foundation Trust. This chemistry was developed within the NHS and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint Table 1 : Limit of detection. Qualitative detection of artificial SARS-COV-2 RNA in 12 independent serial dilutions. Highlighted lines were used to calculate the limit of detection using logistic regression. Calculated LOD = 37.1 genome copies / μl. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity

Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Online First: Epub Date

Optimization of SARS-CoV-2 detection by RT-QPCR without RNA extraction

Preliminary optimisation of a simplified sample preparation method to permit direct detection of SARS-CoV-2 within saliva samples using reversetranscription loop-mediated isothermal amplification (RT-LAMP)

Online First: Epub Date

A simple direct RT-LAMP SARS-CoV-2 saliva diagnostic

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Not All Sequence Tags Are Created Equal: Designing and Validating Sequence Identification Tags Robust to Indels

Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484K Spike Mutation in Brazil

Interpreting Diagnostic Tests for SARS-CoV-2

Online First: Epub Date

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Predicting infectious SARS-CoV-2 from diagnostic samples

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252704 doi: medRxiv preprint